Epidemiology & Intervention Research for Tobacco Control

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Frances Stillman, Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT00076921
First received: February 6, 2004
Last updated: April 8, 2013
Last verified: April 2013
  Purpose

To characterize the development of tobacco control capacity with staff from the Chinese Center's for Disease control (CDCs) at the provincial level and to have them develop and implement population-level interventions to build awareness and knowledge concerning the harms of smoking that could help lead to policy action being taken to protect the population from the harms caused by smoking. Compare capacity, policy and, second-hand smoke exposure and smoking rates in selected provinces to national levels.


Condition
Lung Diseases

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Research on China Tobacco Control Epidemiology and Intervention

Resource links provided by NLM:


Further study details as provided by Johns Hopkins Bloomberg School of Public Health:

Primary Outcome Measures:
  • Compare smoking rates and second-hand smoke exposure in 7 provinces to national data. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    A national household survey was conducted. Provincial household surveys that adapted questions from the national survey were administered to gain provincial estimates.


Secondary Outcome Measures:
  • Change or increase in number of tobacco control policies at the provincial level [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Policies in hospital, schools, worksites, government buildings, transportation facilities will be assessed to determine if they have implemented a policy.

  • Determine change in ability to conduct tobacco control strategies. [ Time Frame: 3 years. ] [ Designated as safety issue: No ]
    An assessment of the provinces ability or capacity to conduct tobacco control strategies were compared at baseline and at the end of the project.


Biospecimen Retention:   None Retained

No bio-specimens collected. Sampled nicotine from buildings only.


Enrollment: 15705
Study Start Date: September 2002
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Detailed Description:

China is a particularly critical country for global tobacco control. It has the world's largest number of smokers, approximately 350 million, and the immense market afforded by the 60 percent of men who smoke and the 95 percent of women who do not smoke represents a prize target for the multinational tobacco companies. China has ratified the Framework Convention for Tobacco Control (FCTC) and now needs to implement its provisions across a large and diverse population. In this application, we propose a program of evidence-based community interventions to be implemented at the province and local levels with the overall objective of developing an approach for implementation nationally.

This application builds on a long-standing partnership between the Chinese Center for Disease Control and Prevention (China CDC), the Peking Union Medical College (PUMC) and the Johns Hopkins Bloomberg School of Public Health. That partnership began in 1995 with an agreement to collaborate on the conduct of China's 1996 national smoking survey. Our principal collaborator over those years, Dr. Gong-Huan Yang, is now Deputy Director of the China CDC and responsible for tobacco control at the national level. In the four years of funding to date from the Fogarty International Center (FIC), we have carried out a project in selected communities in three provinces, including urban and rural areas that provide a foundation for the intervention approach in this proposal. Specifically, we have carried out quantitative and qualitative studies to assess barriers to tobacco control and readiness for interventions, measured levels of airborne nicotine in key public environments, and developed capacity-building approaches. Our original FIC supported study involved three countries, China, Mexico and Brazil. However, this application will focus solely on China, as the latter two countries developed the necessary infrastructure and capacity to conduct research, publish their research findings, and seek further grants and government funding to sustain progress.

This application proposes a tobacco control study that will involve 7 provinces in a CDC-led initiative to develop a systematic mix of approaches. The plan uses strategies based on experiences from our work in China and from the American Stop Smoking Intervention Study for Cancer Prevention (ASSIST) and anticipates barriers that have been identified in the data collected to date. In the intervention provinces, the China CDC will team with the provincial-level CDCs to assess capacity for tobacco control and the current status of tobacco control, using an adapted version of the Strength of Tobacco Control (SOTC) index developed for evaluating ASSIST. This systematic characterization will highlight capacity needs. An extensive capacity development program, based in distance-based methods, will be used. We have the overall objective of preparing the China CDC to implement a proven approach to tobacco control at the national level. A household survey will be conducted and compared to the national survey results. Second-hand smoking will be assessed in selected locations in the 7 provinces.

  Eligibility

Ages Eligible for Study:   15 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Household representatives in 7 selected provinces will complete a survey.

Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00076921

Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
Investigators
Principal Investigator: Frances Stillman Johns Hopkins University
  More Information

Publications:
Responsible Party: Frances Stillman, Associate Professor, Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT00076921     History of Changes
Other Study ID Numbers: 1209, 5R01HL073699
Study First Received: February 6, 2004
Last Updated: April 8, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014